Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of “Buy” from Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been given a consensus rating of “Buy” by the thirteen analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $107.00.

A number of equities research analysts have issued reports on the company. Morgan Stanley started coverage on Monopar Therapeutics in a research report on Friday, January 9th. They issued an “overweight” rating and a $115.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. BTIG Research reiterated a “buy” rating and issued a $104.00 price target on shares of Monopar Therapeutics in a research note on Monday, February 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd.

Monopar Therapeutics Trading Down 1.8%

NASDAQ:MNPR opened at $55.25 on Wednesday. Monopar Therapeutics has a 12-month low of $26.06 and a 12-month high of $105.00. The firm has a market cap of $369.07 million, a PE ratio of -16.06 and a beta of 1.58. The stock has a fifty day moving average price of $60.48 and a 200 day moving average price of $70.69.

Insider Buying and Selling at Monopar Therapeutics

In other news, CFO Quan Anh Vu acquired 1,500 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was acquired at an average cost of $69.95 per share, with a total value of $104,925.00. Following the transaction, the chief financial officer owned 1,500 shares in the company, valued at approximately $104,925. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently bought and sold shares of the business. AlphaQuest LLC raised its stake in Monopar Therapeutics by 8.5% in the third quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock valued at $158,000 after buying an additional 151 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Monopar Therapeutics in the 3rd quarter valued at about $28,000. BNP Paribas Financial Markets increased its holdings in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Monopar Therapeutics during the 2nd quarter worth about $34,000. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Monopar Therapeutics during the 4th quarter worth about $65,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.